Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, attracted the market's attention thanks to excellent midstage clinical ...

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Eli Lilly & Co. (NYSE: LLY) launched its own GLP-1/GIP dual agonist treatment for obesity, Zepbound, in December 2023.

as well as an annual capacity of over 1 billion oral VK2735 tablets. “These API (active pharmaceutical ingredient) and final finished product capacities are further expandable at Viking’s ...

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity. Under the ...